Loading clinical trials...
Loading clinical trials...
A Phase IIB, Randomized, Double Blinded, Placebo Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of MEDI6570 in Participants With a Prior Myocardial Infarction and Persistent Inflammation
Conditions
Interventions
MEDI6570
Placebo
Locations
84
United States
Research Site
Mobile, Alabama, United States
Research Site
Beverly Hills, California, United States
Research Site
Covina, California, United States
Research Site
Northridge, California, United States
Research Site
Northridge, California, United States
Research Site
Torrance, California, United States
Start Date
November 4, 2020
Primary Completion Date
November 8, 2023
Completion Date
November 8, 2023
Last Updated
February 21, 2025
NCT06216847
NCT07149688
NCT07186582
NCT07062432
NCT05834673
NCT06695273
Lead Sponsor
AstraZeneca
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions